In this regard it is also important to state that mTORC1 hyperactivation has been shown to contribute to the growth defects of mice lacking ß-glucuronidase (a model for MPS-VII) or Arsb, thereby providing an alternative therapeutic approach to specifically correct chondrocyte defects in MPS disorders (38). Here, ARSB is linked to mucopolysaccharidosis type 7.